

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



(Scan this code to view Draft Red Herring Prospectus)

PUBLIC ANNOUNCEMENT



Goldline Pharmaceutical Limited

GOLDLINE PHARMACEUTICAL LIMITED

Goldline Pharmaceutical Limited (the “**Issuer**” or our “**Company**”) was incorporated on August 02, 2004 as ‘Goldline Pharmaceutical Private Limited’, a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated August 02, 2004 issued by the Registrar of Companies, Maharashtra at Mumbai. Further, our Company was converted into a public limited company pursuant to a resolution passed by the Shareholders in an extraordinary general meeting held on July 18, 2013 and consequently the name of our Company was changed to ‘Goldline Pharmaceutical Limited’ and a fresh certificate of incorporation dated September 23, 2013 was issued by the Registrar of Companies, Maharashtra at Mumbai. The corporate identity number of our Company is U51397MH2004PLC147806. For details of change in Registered Office of our Company, please refer to the chapter titled “**History and Certain Corporate Matters**” on page 171 of the Draft Red Herring Prospectus.

Corporate Identity Number: U51397MH2004PLC147806

Registered Office: 103, F-1, Leela Apartment, Shilpa HSG Society, Near Saptagiri Nagar, Shanidham, Narendra Nagar, Nagpur – 440 015, Maharashtra, India;

Corporate Office: N.A.; Telephone: +91 712 278 6666; **Contact Person:** Ruchi Sanket Modi, Company Secretary & Compliance Officer;

Website: www.goldlinepharma.in; E-mail: info@goldlinepharma.in

DETAILS OF THE ISSUE

INITIAL PUBLIC OFFER OF UPTO 30,00,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (“**EQUITY SHARES**”) OF OUR COMPANY AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [●] PER EQUITY SHARE) FOR CASH, AGGREGATING UP TO ₹ [●] LACS (“**PUBLIC ISSUE**”) OUT OF WHICH [●] EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING ₹ [●] LACS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE “**MARKET MAKER RESERVATION PORTION**”). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF [●] EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ [●] LACS IS HEREINAFTER REFERRED TO AS THE “**NET ISSUE**”. THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE [●] % AND [●] % RESPECTIVELY OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BRLM AND WILL BE ADVERTISED IN [●] EDITIONS OF [●] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER), [●] EDITIONS OF [●] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER, AND MARATHI EDITIONS OF [●], A REGIONAL LANGUAGE NEWSPAPER (MARATHI, BEING THE REGIONAL LANGUAGE OF MAHARASHTRA, WHERE OUR REGISTERED OFFICE IS SITUATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE SME PLATFORM OF BSE LIMITED (“**BSE**”) FOR THE PURPOSES OF UPLOADING ON ITS WEBSITE IN ACCORDANCE WITH SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE “**SEBI ICDR REGULATIONS**”).

This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (“**SCRR**”) read with Regulation 229(2) of the SEBI ICDR Regulations and in compliance with Regulation 253(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“**QIBs**”) (the “**QIB Portion**”), provided that our Company may, in consultation with the Book Running Lead Manager, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations (“**Anchor Investor Portion**”), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Investors, wherein (a) one third of the portion available to Non-Institutional Investors shall be reserved for Applicants with Application size of more than two lots and up to such lots equivalent to not more than ₹10 lakhs; (b) two third of the portion available to Non-Institutional Investors shall be reserved for Applicants with Application size of more than ₹10 lakhs; and (c) any unsubscribed portion in either of the sub-categories specified in clauses (a) or (b), may be allocated to Applicants in the other sub-category of Non-Institutional Investors and not less than 35% of the Net Issue shall be available for allocation to Individual Investors who apply for minimum application size in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Issue Price. All Bidders are required to participate in the Issue by mandatorily utilizing the Application Supported by Blocked Amount (“**ASBA**”) process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks (“**SCSBs**”) or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see “**Issue Procedure**” on page 284 of the Draft Red Herring Prospectus.

This public announcement is made in compliance with Regulation 247 of the SEBI ICDR Regulation along with Notification no.: F. No. SEBI/LADNRO/GN/2025/233 dated March 3, 2025 and Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) (Amendment) Regulations, 2025, to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake initial public offering of its Equity Shares pursuant to the Issue and had filed the DRHP dated September 30, 2025 which has been filed with SME Platform of BSE Limited (“**BSE**”).

In relation to above, the DRHP filed SME Platform of BSE Limited (“**BSE**”) shall be made available to the public for comments, if any, for a period of at least 21 days from the date of such filing by hosting it on the respective websites of the Stock Exchange i.e., BSE Limited at www.bsesme.com, website of the Company at www.goldlinepharma.in and the website of the Book Running Lead Manager to the Issue i.e., Cumulative Capital Private Limited at www.cumulativecapital.group (“**BRLM**”). Our Company hereby invites the members of the public to give comments on the DRHP filed with SME Platform of BSE Limited with respect to disclosures made in the DRHP. The members of the public are requested to send a copy of their comments to SME Platform of BSE Limited and/or to the Company Secretary and Compliance Officer of our Company and/or the BRLM and/or Registrar to the Issue at their respective addresses mentioned herein below in relation to the Issue on or before 5:00 p.m. on the 21st day from the aforesaid date of filing the DRHP with SME Platform of BSE Limited.

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the issue. For taking an investment decision, investors must rely on their own examination of our Company and the issue, including the risks involved. The Equity Shares in the Issue have not been recommended or approved by the Securities and Exchange Board of India (“**SEBI**”), nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the investors is invited to “**Risk Factors**” on page 22 of the Draft Red Herring Prospectus. Any decision to invest in the Equity Shares described in the DRHP may only be made after the Red Herring Prospectus (“**RHP**”) has been filed with the RoC and must be made solely on the basis of such RHP as there may be material changes in the RHP from the DRHP. The Equity Shares, when offered, through the RHP, are proposed to be listed on the SME Platform of BSE Limited.

For details of the main objects of our Company as contained in its Memorandum of Association, see “**History and Certain Corporate Matters**” on page 171 of the Draft Red Herring Prospectus. The liability of the members of our Company is limited. For details of the share capital, capital structure of our Company, the names of the signatories to the Memorandum of Association and the number of shares of our Company subscribed by them of our Company, please see “**Capital Structure**” beginning on page 70 of the Draft Red Herring Prospectus.

BOOK RUNNING LEAD MANAGER	REGISTRAR TO THE ISSUE	COMPANY
 CUMULATIVE CAPITAL PRIVATE LIMITED Address: 321, 3rd Floor, C Wing, 215 Atrium Co. Op Premises, Andheri Kurla Road, Hanuman Nagar-400093, Andheri Mumbai Telephone: +91 8200052280 /+91-9936798144 E-mail: contact@cumulativecapital.group Website: www.cumulativecapital.group Investor Grievance E-mail: contact@cumulativecapital.group Contact Person: Jigar Bhanushali / Parin Dhanesha SEBI Registration Number: INM000013129	 Bigshare Services Private Limited Address: S6-2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East) Mumbai – 400 093, Maharashtra, India. Telephone: +91 22 6263 8200 Facsimile: +91 22 6263 8299 Email: ipo@bigshareonline.com Website: www.bigshareonline.com Contact Person: Ganesh Shinde SEBI Registration Number: INR000001385	 GOLDLINE PHARMACEUTICAL LIMITED 103, F-1, Leela Apartment, Shilpa HSG Society, Near Saptagiri Nagar, Shanidham, Narendra Nagar, Nagpur — 440 015, Maharashtra, India Telephone: +91 712 278 6666 E-mail: info@goldlinepharma.in Website: www.goldlinepharma.in Contact Person: Ruchi Sanket Modi, Company Secretary and Compliance Officer CIN: U51397MH2004PLC147806

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP dated September 30, 2025.

GOLDLINE PHARMACEUTICAL LIMITED
on behalf of the Board of Directors

Place: Nagpur
Date: October 03, 2025

Sd/-
Ruchi Sanket Modi
Company Secretary & Compliance Officer

Goldline Pharmaceutical Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public Offer of its Equity Shares and has filed the DRHP dated September 30, 2025 with Stock Exchange. The DRHP shall be available on the website of the Stock Exchange i.e., BSE Limited at www.bsesme.com, website of the Company at www.goldlinepharma.in and the website of the Book Running Lead Manager to the Issue i.e., Cumulative Capital Private Limited at www.cumulativecapital.group. Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risks, please see the section entitled “**Risk Factors**” on page 22 of the Draft Red Herring Prospectus. Potential investors should not rely on the DRHP filed with the Stock Exchanges for making any investment decision, and should instead rely on the RHP, for making investment decision.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933 (the “**U.S. Securities Act**”) or any state securities law in United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to the registration requirements of the U. S. Securities Act and applicable U.S. state securities laws. This announcement has been prepared for publication in India and may not be released in the United States.

This announcement does not constitute an offer of securities for sale in any jurisdiction, including the United States, and any securities described in this announcement may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933, as amended, or an exemption from registration. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and management, as well as financial statements. There will be no public offering of the Equity Shares in the United States.